{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T11:51:56Z","timestamp":1778932316493,"version":"3.51.4"},"reference-count":50,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.eimc.2017.11.014","type":"journal-article","created":{"date-parts":[[2017,12,31]],"date-time":"2017-12-31T04:08:06Z","timestamp":1514693286000},"page":"302-311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Diagn\u00f3stico y abordaje terap\u00e9utico de la infecci\u00f3n tuberculosa latente"],"prefix":"10.1016","volume":"36","author":[{"given":"Jos\u00e9","family":"Dom\u00ednguez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Latorre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Santin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimc.2017.11.014_bib0255","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMra1405427","article-title":"Latent Mycobacterium tuberculosis infection","volume":"372","author":"Campion","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2017.11.014_bib0260","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S0140-6736(00)02742-2","article-title":"Specific immune-based diagnosis of tuberculosis","volume":"356","author":"Andersen","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2017.11.014_bib0265","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1128\/CVI.00364-07","article-title":"Comparison of two commercially available gamma interferon blood tests for immunodiagnosis of tuberculosis","volume":"15","author":"Dominguez","year":"2008","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.eimc.2017.11.014_bib0270","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1164\/rccm.201405-0967OC","article-title":"Risk assessment of tuberculosis in immunocompromised patients. A TBNET Study","volume":"190","author":"Sester","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.eimc.2017.11.014_bib0275","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1164\/rccm.201006-0974OC","article-title":"Negative and positive predictive value of a whole-blood interferon-gamma release assay for developing active tuberculosis: An update","volume":"183","author":"Diel","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.eimc.2017.11.014_bib0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183258","article-title":"QuantiFERON\u00ae-TB Gold In-Tube for contact screening in BCG-vaccinated adults: A longitudinal cohort study","volume":"12","author":"Mu\u00f1oz","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.eimc.2017.11.014_bib0285","article-title":"QuantiFERON-TB gold in-tube as a confirmatory test for tuberculin skin test in tuberculosis contact tracing: A non-inferiority clinical trial","author":"Mu\u00f1oz","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2017.11.014_bib0290","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.jinf.2016.09.008","article-title":"First characterization of the CD4 and CD8 T-cell responses to QuantiFERON-TB Plus","volume":"73","author":"Petruccioli","year":"2016","journal-title":"J Infect"},{"key":"10.1016\/j.eimc.2017.11.014_bib0295","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.cmi.2016.05.006","article-title":"Equal sensitivity of the new generation QuantiFERON-TB Gold plus in direct comparison with the previous test version QuantiFERON-TB Gold IT","volume":"22","author":"Hoffmann","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.eimc.2017.11.014_bib0300","doi-asserted-by":"crossref","first-page":"30617","DOI":"10.1038\/srep30617","article-title":"Evaluation of QuantiFERON-TB Gold Plus for detection of Mycobacterium tuberculosis infection in Japan","volume":"6","author":"Yi","year":"2016","journal-title":"Sci Rep."},{"key":"10.1016\/j.eimc.2017.11.014_bib0305","first-page":"303","volume":"34","author":"Santin","year":"2016","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2017.11.014_bib0310","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1186\/1471-2334-12-379","article-title":"Negative effect of smoking on the performance of the QuantiFERON TB gold in tube test","volume":"12","author":"Aabye","year":"2012","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.eimc.2017.11.014_bib0315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182998","article-title":"Assessment of the influence of direct tobacco smoke on infection and active TB management","volume":"12","author":"Altet","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.eimc.2017.11.014_bib0320","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.tube.2011.01.001","article-title":"A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosis","volume":"91","author":"Ruhwald","year":"2011","journal-title":"Tuberculosis"},{"key":"10.1016\/j.eimc.2017.11.014_bib0325","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jinf.2017.07.004","article-title":"Use of IFN-g and IP-10 detection in the diagnosis of latent tuberculosis infection in patients with inflammatory rheumatic diseases","volume":"75","author":"Villar-Hernandez","year":"2017","journal-title":"J Infect"},{"key":"10.1016\/j.eimc.2017.11.014_bib0330","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.jinf.2014.06.013","article-title":"IP-10 is an accurate biomarker for the diagnosis of tuberculosis in children","volume":"69","author":"Latorre","year":"2014","journal-title":"J Infect"},{"key":"10.1016\/j.eimc.2017.11.014_bib0335","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1183\/09031936.00129412","article-title":"Dried plasma spots in the diagnosis of tuberculosis: IP-10 release assay on filter paper","volume":"42","author":"Aabye","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.eimc.2017.11.014_bib0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmicb.2014.00517","article-title":"Immunogenicity of 60 novel latency-related antigens of Mycobacterium tuberculosis","volume":"5","author":"Serra-Vidal","year":"2014","journal-title":"Front Microbiol"},{"key":"10.1016\/j.eimc.2017.11.014_bib0345","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S2213-2600(16)30436-2","article-title":"Safety and efficacy of the C-Tb skin test to diagnose Mycobacterium tuberculosis infection, compared with an interferon gamma release assay and the tuberculin skin test: A phase 3, double-blind, randomised, controlled trial","volume":"5","author":"Ruhwald","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.eimc.2017.11.014_bib0350","doi-asserted-by":"crossref","DOI":"10.21037\/jlpm.2017.10.06","article-title":"Could IFN-gamma levels in serial QuantiFERON predict TB development in young children?","author":"Villar-Hernandez","year":"2017","journal-title":"J Lab Precis Med"},{"key":"10.1016\/j.eimc.2017.11.014_bib0355","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S2213-2600(17)30060-7","article-title":"Serial QuantiFERON testing and tuberculosis disease risk among young children: An observational cohort study","volume":"5","author":"Andrews","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.eimc.2017.11.014_bib0360","first-page":"638","volume":"196","author":"Nemes","year":"2017","journal-title":"Optimization and interpretation of serial QuantiFERON testing to measure acquisition of Mycobacterium tuberculosis infection"},{"key":"10.1016\/j.eimc.2017.11.014_bib0365","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/S0140-6736(15)01316-1","article-title":"A prospective blood RNA signature for tuberculosis disease risk","volume":"387","author":"Zak","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2017.11.014_bib0370","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cell.2016.08.072","article-title":"Article A. Functional role for antibodies in tuberculosis","volume":"167","author":"Lu","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.eimc.2017.11.014_bib0375","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1056\/NEJMcibr1613268","article-title":"Antibodies to Mycobacterium tuberculosis","volume":"376","author":"Casadevall","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2017.11.014_bib0380","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jinf.2015.07.009","article-title":"Assessment of CD27 expression as a tool for active and latent tuberculosis diagnosis","volume":"71","author":"Petruccioli","year":"2017","journal-title":"J Infect"},{"key":"10.1016\/j.eimc.2017.11.014_bib0385","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1473-3099(14)70884-9","article-title":"Assessment of the novel T-cell activation marker-tuberculosis assay for diagnosis of active tuberculosis in children: A prospective proof-of-concept study","volume":"14","author":"Portevin","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.eimc.2017.11.014_bib0390","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1378\/chest.76.6_Supplement.771","article-title":"Basic mechanisms of chemotherapy","volume":"76","author":"Mitchinson","year":"1979","journal-title":"Chest"},{"key":"10.1016\/j.eimc.2017.11.014_bib0395","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1183\/09031936.00079310","article-title":"Series \u00abupdate on tuberculosis\u00bb: Treatment of latent infection with Mycobacterium tuberculosis: Update 2010","volume":"37","author":"Leung","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.eimc.2017.11.014_bib0400","first-page":"1","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis, infection","volume":"49","year":"2000","journal-title":"MMWR Recomm Rep."},{"key":"10.1016\/j.eimc.2017.11.014_bib0405","article-title":"Isoniazid for preventing tuberculosis in non-HIV infected persons","volume":"2","author":"Smieja","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eimc.2017.11.014_bib0410","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000171.pub3","article-title":"Treatment of latent tuberculosis infection in HIV-infected persons","author":"Akolo","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eimc.2017.11.014_bib0415","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/cid\/ciu849","article-title":"Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: The TB\/HIV in Rio (THRio) study","volume":"60","author":"Golub","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2017.11.014_bib0420","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"An official ATS statement: Hepatotoxicity of antituberculosis therapy","volume":"174","author":"Saukkonen","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.eimc.2017.11.014_bib0425","doi-asserted-by":"crossref","first-page":"419","DOI":"10.7326\/M14-1019","article-title":"Treatment of latent tuberculosis infection a network meta-analysis","volume":"161","author":"Stagg","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eimc.2017.11.014_bib0430","doi-asserted-by":"crossref","unstructured":"Hong Kong Chest Service, Tuberculosis Research Centre, Madras, and British Medical Research Council. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis. 1992;145:36-41.","DOI":"10.1164\/ajrccm\/145.1.36"},{"key":"10.1016\/j.eimc.2017.11.014_bib0435","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2017.11.014_bib0440","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jamapediatrics.2014.3158","article-title":"Treatment for preventing tuberculosis in children and adolescents: A randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid","volume":"169","author":"Villarino","year":"2015","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.eimc.2017.11.014_bib0445","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1097\/QAD.0000000000001098","article-title":"Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons","volume":"30","author":"Sterling","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2017.11.014_bib0450","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.cmi.2016.08.024","article-title":"Preventing the spread of multidrug-resistant tuberculosis and protecting contacts of infectious cases","volume":"23","author":"Fox","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.eimc.2017.11.014_bib0455","doi-asserted-by":"crossref","first-page":"912","DOI":"10.5588\/ijtld.13.0028","article-title":"Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012","volume":"18","author":"Bamrah","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.eimc.2017.11.014_bib0460","unstructured":"Seddon JA, Fred D, Amanullah F, Schaaf HS, Starke JR, Keshavjee S, et al. Post-exposure management of multidrug-resistant tuberculosis contacts: evidence-based recommendations. Policy Brief No 1. Dubai, United Arab Emirates: Harvard Medical School Center for Global Health Delivery-Dubai; 2015."},{"key":"10.1016\/j.eimc.2017.11.014_bib0465","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1097\/TP.0000000000001224","article-title":"Prevention and management of tuberculosis in transplant recipients: From guidelines to clinical practice","volume":"100","author":"Mu\u00f1oz","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.eimc.2017.11.014_bib0470","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1093\/cid\/civ156","article-title":"Tuberculosis prophylaxis with levofloxacin in liver transplant patients is associated with a high incidence of tenosynovitis: Safety analysis of a multicenter randomized trial","volume":"60","author":"Torre-Cisneros","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2017.11.014_bib0475","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/cid\/civ639","article-title":"Tolerability of fluoroquinolones in management of latent","volume":"61","author":"Tien","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2017.11.014_bib0480","first-page":"1766","volume":"52","author":"Carmona","year":"2005","journal-title":"Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists"},{"key":"10.1016\/j.eimc.2017.11.014_bib0485","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/cid\/ciu796","article-title":"Prevention of anti-tumor necrosis factor-associated tuberculosis: A 10-year longitudinal cohort study","volume":"60","author":"Mu\u00f1oz","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2017.11.014_bib0490","first-page":"36","article-title":"Documento de consenso sobre la prevenci\u00f3n y el tratamiento de la tuberculosis en pacientes candidatos a tratamiento biol\u00f3gico","volume":"52","author":"Mir","year":"2016","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.eimc.2017.11.014_bib0495","first-page":"18","article-title":"Actualizaci\u00f3n del tratamiento de la tuberculosis en ni\u00f1os","author":"Mellado-Pe\u00f1a","year":"2017","journal-title":"An Pediatr (Barc)"},{"key":"10.1016\/j.eimc.2017.11.014_bib0500","first-page":"701","article-title":"Treatment completion in latent tuberculosis infection at specialist tuberculosis units in Spain","volume":"14","author":"Anibarro","year":"2010","journal-title":"Int J Tuberc Lung Dis"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X17303786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X17303786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,25]],"date-time":"2018-08-25T00:23:49Z","timestamp":1535156629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X17303786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0213005X17303786"],"URL":"https:\/\/doi.org\/10.1016\/j.eimc.2017.11.014","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagn\u00f3stico y abordaje terap\u00e9utico de la infecci\u00f3n tuberculosa latente","name":"articletitle","label":"Article Title"},{"value":"Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eimc.2017.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.","name":"copyright","label":"Copyright"}]}}